+357 96 030922
info@marketpublishers.com

Scleroderma Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Immunosuppressors, ERA, CCBs, PA), By Indication (Systemic, Localized), By Region, And Segment Forecasts, 2025 - 2030

https://marketpublishers.com/r/SEDC0DC1F4D3EN.html
Date: November 2024
Pages: 70
Price: US$ 5,950.00 (Single User License)
ID: SEDC0DC1F4D3EN

Abstracts

This report can be delivered to the clients within 3 Business Days

Scleroderma Therapeutics Market Growth & Trends

The global scleroderma therapeutics market size is expected treach USD 3.44 billion by 2030, registering a CAGR of 5.0% from 2025 t2030, according ta new report by Grand View Research, Inc. The market growth is credited tthe availability of various therapies used off-label, such as small molecule therapies including branded, generics, and OTC drugs.

The mix of several indications and drug classes engenders a fragmented market with multiple players. Roche is the dominant company with biologic immunosuppressants, Actemra/RoActemra, Cellcept, and Rituxan contributing majorly tthe company’s share. Pfizer and Eli Lilly are the key companies in the market. Over the forecast period, new entrants including Boehringer Ingelheim, Corbus Pharmaceuticals, and Fibrocell will marginally displace the share of established firms in this market.

The on-label market is in the development phase. Supplemental indication approval is one of the most common strategies adopted by market participants. For example, riociguat by Bayer was previously used for PAH and currently, it is under clinical trials for the treatment of SSc-related digital ulcers. There are several other pharmaceutical companies following suit as this strategy favors the pharmaceutical industry in offsetting high development costs and in reaping larger benefits from one molecule already developed and present in the market.

Scleroderma Therapeutics Market Report Highlights

The immunosuppressors segment accounted for the largest share of 27.4% in 2024, and is likely tmaintain the dominance throughout the forecast years

High preference for immunosuppressants owing tthe favorable reimbursement scenariassociated with this drug class supports its dominant market share

Systemic scleroderma indication segment accounted for the major market share and will expand further due tuse of high-priced immunosuppressants

The U.S. market accounted for 90.6% share of the North America scleroderma therapeutics market in 2024. Expected label expansions and expected launch of first-in-class therapies coupled with an evolving reimbursement landscape for orphan drugs support continual scleroderma therapeutics market growth

Europe trails with a lower share as compared tthe U.S. majorly due thigher use of generics and biosimilars for off-label treatment of scleroderma

+357 96 030922
info@marketpublishers.com

Contents

CHAPTER 6. SCLERODERMA THERAPEUTICS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS BY DRUG CLASS AND INDICATION

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

CHAPTER 7. COMPETITIVE LANDSCAPE

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Scleroderma Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Immunosuppressors, ERA, CCBs, PA), By Indication (Systemic, Localized), By Region, And Segment Forecasts, 2025 - 2030

Product link: https://marketpublishers.com/r/SEDC0DC1F4D3EN.html

Price: US$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/SEDC0DC1F4D3EN.html